PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143391
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2143391
Metagenomics market size was valued at US$ 2,770.8 Million in 2025, expanding at a CAGR of 14.3% from 2026 to 2033.
'Metagenomics' refers to the culture-independent genomic analysis of microbial assemblages extracted directly from environmental samples and/or host-related samples. It provides an extensive investigation of the taxonomic diversity, functionality, and genetic variability of the organisms existing in the complex ecological community. A general metagenomic workflow consists of sample collection and cultivation, total community DNA fragmenting and extraction , library preparation through shotgun or amplicon DNA sequencing, high-throughput next-generation sequencing followed by a bioinformatics pipeline, including filtering, assembly, gene prediction, sorting the data based on metagenome-assembled genomes, and, finally, functional annotation through reference databases. This integrated workflow enables comprehensive characterisation of microbial communities and their functional capabilities.
Metagenomics Market- Market Dynamics
Adoption In Clinical Diagnostics To Fuel Market Demand
The adoption of metagenomics in clinical diagnostics is mainly fueled by the increasing demand for a quick, wide-spectrum, and pathogen-agnostic detection method for diagnosing infectious diseases when culture and targeted PCR fail to provide accurate identification. As seen from the general metagenomics market, in the diagnostics sector, it would involve not only detection of multiple pathogens but also assessing their potential for antimicrobial resistance via metagenomic sequencing. For example, in June 2026, as per the UK government, 48.4% of respondents were already using AI technologies, indicating an existing customer base ready to adopt AI technology applications such as diagnostics. In the report cited, AI diagnostics are mentioned as one of the most urgently needed technical skills, and it is stated that there is increasing use of AI technology in order to improve diagnostic accuracy as well as to automate genome sequencing.
According to the report, AI diagnostics are about to become the new standard of care, and AI will help radiologists and pathologists in detecting abnormalities such as early-stage tumors and cardiovascular risks. The UK biobank provides genomic and health information anonymously for 500,000 individuals. These advancements are accelerating metagenomics adoption by strengthening AI-enabled, comprehensive, and rapid clinical pathogen detection.
The Global Metagenomics market is segmented on the basis of Product, Technology, Workflow, Application, and Region.
In terms of technology, shotgun sequencing represents a significant segment in the Metagenomics market because of its ability to carry out an unbiased analysis of the entire microbial community and thus make available a huge range of microbes and genes in the environmental, clinical, and research industries and even in the pharmaceutical industry. In 2025, Illumina offered advanced sequencing technologies such as Illumina DNA Prep and the Illumina NovaSeq and NextSeq sequencing systems along with the DRAGEN Metagenomics Pipeline, which is a sequencing pipeline for high-throughput analysis of the microbe community. This technological advancement strengthens shotgun sequencing's role in enabling comprehensive microbial community characterization.
Metagenomics Market- Geographical Insights
North America holds a prominent position in the Metagenomics market due to the presence of major companies, huge investments into R&D, and fast development of sequencing technologies. For instance, in June 2025, according to the Journal of BioX Research Org., it is indicated that sequencing technologies develop fast: with the help of high-throughput sequencing, it is possible to sequence hundreds of millions of DNA pieces at once. Also, sequence clusters developed by Illumina can amplify the original pieces up to 1 million times in order to obtain signals. Moreover, the sequencing technology of Applied Biosystems' SOLiD allows producing 2-4 Gb of sequences in one sequencing cycle using the read lengths from 25 to 35 base pairs, while the FLX technology of Roche/454 makes it possible to produce 250 nucleotides and 100 Mb of sequences in 8 hours. These advances demonstrate the increasing speed, throughput, and data-generation capacity of sequencing technologies, supporting their expanding application in genomic research and biomedical analysis.
The Metagenomics market globally is characterized by high competition. The company leaders pay much attention to technological innovation that is connected with sequencing and bioinformatics solutions in order to take more of the market share. Another trend typical of this market is mergers and collaborations because this way companies can leverage their new product lines, gain experience and knowledge in the field of sequencing and bioinformatics, and contribute to the development of microbiome research and precision medicine. Some of the main companies in the market are Illumina, Thermo Fisher Scientific, QIAGEN, F. Hoffmann-La Roche, and Bio-Rad Laboratories. In July 2025, QIAGEN introduced QIAseq xHYB Long-Read Panels and extended its NGS line by long-read sequencing technologies suitable for microbial genomics and metagenomics. It is a line of long-read sequencing tools with targeted enrichment. Therefore, the company keeps innovating, and this is vital for its further development in the area of next-generation metagenomics sequencing.
In April 2026, Oxford Nanopore Technologies has expanded its strategic alliance with Cepheid following the successful conclusion of the first stage of the strategic partnership. The second stage of the strategic partnership is aimed at ensuring the presence of the genomic workflow tools that can be used for the analysis of infections from complex pathogens.
In May 2025, Roche will sign a strategic alliance with Broad Clinical Labs for the purposes of piloting and developing the applications that use Roche's SBX technology. The first phase of the strategic alliance will focus on the development of whole genome sequencing applications that are relevant to broader applications of microbial and metagenomic sequencing.